The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 2, 2011, Pages 128-134

  Weir, S J ^a   Patton, L ^b   Castle, K ^b   Rajewski, L ^a   Kasper, J ^c   Schimmer, A D ^d  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b Beckloff Associates Inc   (United States)

^c The Leukemia & Lymphoma Society   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

drug repositioning; intracellular iron chelation; leukemia

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTIFUNGAL AGENT; CICLOPIROX; DEFEROXAMINE; IRON;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BURNING SENSATION; CHELATION; CONTACT DERMATITIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG REPOSITIONING; DRUG STRUCTURE; DRY SKIN; ERYTHEMA; FACE EDEMA; HEADACHE; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; LD 50; METHEMOGLOBINEMIA; MYCOSIS; NAIL DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; RASH; REVIEW; SKIN INFECTION; SKIN IRRITATION; SKIN PAIN; SKIN REDNESS; TREATMENT INDICATION;

ANIMALS; ANTIFUNGAL AGENTS; CELL DEATH; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DERMATOMYCOSES; DOGS; DRUG REPOSITIONING; FEMALE; FUNGI; HEMATOLOGIC NEOPLASMS; HUMANS; IRON CHELATING AGENTS; MALE; MICE; PYRIDONES; RATS;

EID: 79952253716     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01172.x     Document Type: Review

References (22)

1. Sehgal VN., (1976) Ciclopirox: a new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses. British Journal of Dermatology, 95, 83-88.
2. Burnett BP, Mitchell CM., (2008) Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole. Cutis, 82, 273-280.
3. Chosidow O, Maurette C, Dupuy P., (2003) Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology, 206, 233-240. (Pubitemid 36407831)
4. Dupuy P, Maurette C, Amoric JC, Chosidow O., (2001) Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. British Journal Dermatology, 144, 1033-1037.
5. Squire RA, Goode K., (2002) A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. Journal of Dermatology Treatment, 13, 51-60. (Pubitemid 34670361)
6. Avner S, Nir N, Henri T., (2005) Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. Journal of Dermatology Treatment, 16, 327-330. (Pubitemid 43170204)
7. Balabanov S, Gontarewicz A, Ziegler P, et al. (2007) Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood, 109, 1701-1711. (Pubitemid 46239605)
8. Eberhard Y, McDermott SP, Wang X, et al. (2009) Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood, 114, 3064-3073.
9. Barabe F, Kennedy JA, Hope KJ, Dick JE., (2007) Modeling the initiation and progression of human acute leukemia in mice. Science, 316, 600-604. (Pubitemid 46683146)
10. Warner JK, Wang JC, Takenaka K, Doulatov S, McKenzie JL, Harrington L, Dick JE., (2005) Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia, 19, 1794-1805. (Pubitemid 41486158)
11. Clement PM, Hanauske-Abel HM, Wolff EC, Kleinman HK, Park MH., (2002) The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. International Journal of Cancer, 100, 491-498.
12. Linden T, Katschinski DM, Eckhardt K, Scheid A, Pagel H, Wenger RH., (2003) The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. FASEB Journal, 17, 761-763.
13. Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, Shih J, Yen Y., (2006) A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Molecular Cancer Therapeutics, 5, 586-592.
14. Attia S, Kolesar J, Mahoney MR., (2008) A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Investigational New Drugs, 26, 369-379.
15. Odenike OM, Larson RA, Gajria D, et al. (2008) Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde- thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Investigational New Drugs, 26, 233-239.
16. Kellner HM, Arnold C, Christ OE, Eckert HG, Herok J, Hornke I, Rupp W., (1981) [Investigations on the pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic application]. Arzneimittel-Forschung, 31, 1337-1353. (Pubitemid 12205851)
17. Summary Basis of Approval-Pharmacology Review Loprox Shampoo 1%. NDA Application Number 21-159, Aventis, 2000.
18. Adam W, Peil HG, Savopoulos C, Vanderbeke O., (1981) [Clinical results with the antimycotic agent ciclopiroxolamine (author's transl)]. Arzneimittel-Forschung, 31, 1360-1365. (Pubitemid 12205853)
19. Alpermann HG, Schutz E., (1981) [Studies on the pharmacology and toxicology of ciclopiroxolamine (author's transl)]. Arzneimittel-Forschung, 31, 1328-1332. (Pubitemid 12205849)
20. Product monograph for Apo Ciclopirox (ciclopirox olamine cream USP, 1%) and Loprox Lotion (ciclopirox lotion 1%). Sanofi-Aventis Canada, Inc.; dated June 12, 2006.
21. Product Monograph for Penlac (ciclopirox olamine topical solution w/w) Nail Laquer Sanofi-Aventis Canada Inc, Laval, Quebec; dated May 30, 2006.
22. Product Monograph for Stieprox ciclopirox olamine shampoo 1.5%. Stiefel Canada Inc. Montreal, Quebec; dated February 15, 2006.